Linkedin
Facebook
Twitter
Youtube

23 Feb Cabaletta Bio

Posted at 18:53h in by

Steven Nichtberger, M.D., President and CEO 

Oct. 11 | 10:45am | Oxford Biomedica Ballroom 

Philadelphia, PA 

(NASDAQ: CABA) 

In-person Presentation 

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris, and hemophilia A with FVIII alloantibodies. 

www.cabalettabio.com 

 



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,700 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 11-13, 2022
Park Hyatt Aviara
Carlsbad, CA

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions